Last reviewed · How we verify
Homologous boost schedule
A homologous boost vaccination schedule that enhances immune response by administering the same vaccine formulation multiple times at optimized intervals.
A homologous boost vaccination schedule that enhances immune response by administering the same vaccine formulation multiple times at optimized intervals. Used for COVID-19 prevention (homologous booster schedule).
At a glance
| Generic name | Homologous boost schedule |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Homologous boost schedules involve repeated doses of an identical vaccine to strengthen and broaden the adaptive immune response. This approach is commonly used in infectious disease vaccination to increase antibody titers, expand T-cell populations, and improve immunological memory. The timing and number of boosts are designed to maximize protective immunity.
Approved indications
- COVID-19 prevention (homologous booster schedule)
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Immunogenicity of COVID-19 Vaccine on Heterologous Schedule (PHASE2)
- A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults (PHASE4)
- Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines (PHASE3)
- Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19) (PHASE2)
- 2013/2017 H7N9 Prime-Boost Interval (PHASE2)
- A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (PHASE1)
- Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Homologous boost schedule CI brief — competitive landscape report
- Homologous boost schedule updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI